How to appeal a UnitedHealthcare pediatric epilepsy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for pediatric epilepsy

Cited policy: OptumRx Epidiolex (Cannabidiol) PA Criteria

FDA indications: LGS or Dravet syndrome (ages 1+, originally 2+) or TSC-associated seizures (ages 1+ per Aug 2020 expansion). Diagnosis confirmed by pediatric epileptologist or neurologist. Inadequate response/intolerance to >=2 appropriate AEDs (e.g., clobazam, valproate, rufinamide, lamotrigine, topiramate). LFTs at baseline + months 1, 3, 6 + clinically (interaction with clobazam — desmethyl-clobazam levels increase). Reauth at 6 mo with >=25% seizure reduction or improved seizure-free intervals.

How UnitedHealthcare denies pediatric epilepsy — and how to counter it

Where UnitedHealthcare pushes back: 1) Experimental cannabis-derived therapy; 2) Step therapy: must fail 3+ traditional AEDs first; 3) TSC use off-label; 4) Age <2 yr (using outdated label).

Counter-arguments that hold up: FDA-approved Jun 25, 2018 (LGS + Dravet) and Aug 31, 2020 (TSC). Pharmaceutical-grade purified plant-derived cannabidiol oral solution — DEA-descheduled for the FDA-approved formulation (Apr 2020). GWPCARE-1 Devinsky NEJM 2017 (Dravet) — 43% with >=50% reduction vs 27% placebo. GWPCARE-3/4 Thiele Lancet 2018 + Devinsky NEJM 2018 (LGS) — drop-seizures -43.9% vs -21.8%. GWPCARE-6 Thiele JAMA Neurol 2021 (TSC) — -48.6% vs -26.5%. ILAE Kwan 2010 drug-resistant criteria already met after 2 AED failures. NOT off-label for TSC since Aug 2020.

What UnitedHealthcare typically denies for pediatric epilepsy

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric epilepsy, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the pediatric epilepsy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Epidiolex
• Fintepla
• Diacomit
• Clobazam (Onfi/Sympazan)
• Banzel
• Ztalmy (CDKL5)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.